Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s targeted radionuclide therapeutic and diagnostic candidates for Greater China
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
Four-year research collaboration combines Pfizer’s deep experience in global drug development, including programs utilizing messenger RNA (mRNA), lipid nanoparticles (LNP), and gene therapy, with Beam’s leadership in base editing and mRNA/LNP delivery technologies
Tangent offers ISO/IEC 17025-accredited calibrations and has labs located in both Indianapolis and Huntsville, Alabama
The combination enhances Comar's customer value proposition by adding complementary closure and jar products and related precision mold-making expertise
The hospital has recently launched Radionuclide therapy
Subscribe To Our Newsletter & Stay Updated
